C. Rebordosa

First name
C.
Last name
Rebordosa
Rivero-Ferrer, E., Olesen, M., Plana, E., Aguado, J., Saigi-Morgui, N., Rubino, A., et al. (2022). Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany. Clin Drug Investig. http://doi.org/10.1007/s40261-022-01120-2
Rebordosa, C., Plana, E., Aguado, J., Thomas, S., Garcia-Gil, E., Perez-Gutthann, S., & Castellsague, J. (2018). GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD). Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4448
Rebordosa, C., Aguado, J., Plana, E., Thomas, S., Frances, A., Lei, A., et al. (2019). Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom. Respir Med. http://doi.org/10.1016/j.rmed.2019.04.018
Arana, A., Margulis, A. V., Varas-Lorenzo, C., Bui, C. L., Gilsenan, A., McQuay, L. J., et al. (2020). Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5150
Rebordosa, C., Plana, E., Rubino, A., Aguado, J., Lei, A., Daoud, S., et al. (2021). A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. http://doi.org/10.2147/copd.s301624